MAS825 for Still's disease in children and adults
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new drug called MAS825 for people with Still's disease that is still active despite other treatments. It aims to see if the drug can reduce symptoms like fever, rash, joint pain, or a serious complication called macrophage activation syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old and have a diagnosis of Still's disease.
- Your disease must be active, shown by high CRP or ferritin levels and symptoms like fever, rash, joint inflammation, or other complications.
- You must have tried other biologic treatments and they didn't work well enough or caused side effects.
- You cannot be taking certain other immune-suppressing drugs, and your steroid dose must be within a set limit.
- You must not have serious infections, recent live vaccines, certain cancers, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two injectable medicines (goflikicept and olokizumab) work safely as a second treatment for adults with Still's disease, a rare inflammatory condition. If you've already tried one treatment without enough improvement, this trial may help.
This study will follow people with adult-onset Still's disease or similar autoinflammatory conditions to learn more about these illnesses over time. By participating, you can help doctors better understand and treat these conditions.
This study is for children diagnosed with Kawasaki disease who also develop macrophage activation syndrome (a serious immune complication) within the first month. It aims to better understand and manage this combination.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
Hear when a new Still´s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.